Targeting the antigen processing and presentation pathway to overcome resistance to immune checkpoint therapy
Despite the significant clinical advances with the use of immune checkpoint inhibitors (ICIs) in a wide range of cancer patients, response rates to the therapy are variable and do not always result in long-term tumor regression.The development of ICI-resistant disease is one of the pressing issue in clinical oncology, and the identification of new